Business
Thermo Fisher Receives FDA Approval for NGS-Based Companion Diagnostic for New Non-Small Cell Lung Cancer Treatment
CARLSBAD, Calif., August 11, 2025--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS® (zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim. The test allows clinicians and pathologists to assess if non-small cell lung cancer (NSCLC) tumors harbor human epid
About this update from Thermo Fisher Scientific Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1590,"height":341,"url":"https://media.zenfs.com/en/business-wire.com/080c78d949aa58d24affb4a558de9c4c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IQUtQ57NgLAH7wXZkykWcA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwNjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/080c78d949aa58d24affb4a558de9c4c","width":960,"height":206},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/7KWIz_EIHekCNHnGijnIIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/080c78d949aa58d24affb4a558de9c4c","width":1200,"height":257}},"lazy":false},{"type":"text","content":"Oncomine Dx Target Test approved to identify patients eligible for HERNEXEOS® (zongertinib tablets), the first and only orally administered targeted treatment for HER2 (ERBB2)-mutant NSCLC","length":188,"tagName":"p","attribs":{}},{"type":"text","content":"CARLSBAD, Calif., August 11, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS® (zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim. The test allows clinicians and pathologists to assess if non-small cell lung cancer (NSCLC) tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations.","length":611,"tagName":"p"},{"type":"text","content":"Lung cancer is the second most common cancer in both men and women in the United States, with NSCLC accounting for about 85–90% of all lung cancer cases.1 Among those diagnosed with NSCLC, approximately 2 to 4 percent of patients present with a HER2 mutation.2 The FDA approved HERNEXEOS on August 8, 2025 as the first and only orally administered targeted therapy for adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy. This indication was approved under accelerated approval based on objective resp...